Asset profile
CS1001 Monoclonal Antibody
Monoclonal antibody
Evidence outlook · lead readout
NCT03728556 · Non-Small Cell Lung Cancer Stage III
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT03728556: In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 58 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CS1001 Monoclonal Antibody: this drug | Phase 3 | Monoclonal antibody | PD-L1 | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | ||
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | ||
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| Envafolimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| KL-A167 | Phase 3 | Monoclonal antibody | PD-L1 | ||
| PF-08046054 | Phase 3 | Antibody–drug conjugate | PD-L1 | ||
| HLX43 | Phase 2/3 | Antibody–drug conjugate | PD-L1 | ||
| 177Lu-RAD204 | Phase 1 | Radiopharmaceutical | PD-L1 | ||
| BPI-371153 | Phase 1 | Small molecule | PD-L1 | ||
| IBC-Ab002 | Phase 1 | Monoclonal antibody | PD-L1 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.